• News
  • SAN DIEGO
  • BioTech

Zogenix developing abuse-deterrent painkiller

The San Diego company that makes the powerful new prescription painkiller Zohydro is selling off its migraine therapy business to focus on developing abuse-resistant forms of Zohydro.

Zogenix (Nasdaq: ZGNX) Chief Executive Officer Roger Hawley said the sale will help the company focus on the launch of Zohydro ER while providing capital “to continue the development of two abuse-deterrent formulations” of the opioid.

The company announced in November it would pursue an abuse-deterrent form of the drug.

Health officials around the country worry addicts will crush Zohydro capsules and then snort or inject the drug to get high.

Citing such worries, Massachusetts Gov. Deval Patrick tried to ban the drug, but a federal court blocked the state from enforcing the ban. Patrick has since announced new restrictions on the drug.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Zogenix Inc.

Company Website

12400 High Bluff Dr. Ste., 650
San Diego, CA 92130

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
ZGNX
13.53
  -0.06  
- 0.44%
335,635,000
21.65
8.64

Zogenix Inc. Executive(s):

Roger Hawley

  • Chief Executive Officer

Stephen Farr

  • President

Ann Rhoads

  • Chief Financial Officer